................ 36 Heat Biologics, Inc. Investigational Product: Viagenpumatucel -L Protocol HS110 -201 CONFIDENTIAL Version 4.0; 29 -Oct-2014 Page 14 of 84 6.3.3 End of Treatment Visit (Day 28 ± 7 post last dose) ................................ ............................ 41 6.3.4 Long -term Follow -up Visits ................................ ................................ ................................ 41 6.4 Safety Assessments ................................ ................................